<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078882</url>
  </required_header>
  <id_info>
    <org_study_id>599969</org_study_id>
    <secondary_id>IM101-457</secondary_id>
    <nct_id>NCT02078882</nct_id>
  </id_info>
  <brief_title>Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis</brief_title>
  <acronym>PBC</acronym>
  <official_title>Abatacept For The Treatment Of Primary Biliary Cirrhosis With An Incomplete Biochemical Response To Ursodeoxycholic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christopher Bowlus, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if abatacept (Orencia) is effective in patients
      with primary biliary cirrhosis who do not respond adequately to standard treatment with
      ursodeoxycholic acid (UDCA, Urso, Ursodiol, Actigall).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, active treatment trial to assess the efficacy and safety of abatacept
      in subject with PBC who have had an incomplete biochemical response to UDCA. In this trial,
      20 subjects with PBC who have had an incomplete biochemical response to UDCA will be assigned
      to treatment with weekly subcutaneous injections of 125 mg of abatacept. The treatment phase
      of the study will last 24 weeks with an off-treatment follow up at Week 36.

      Inclusion criteria include:

        -  Confirmed diagnosis of PBC

        -  Alkaline phosphatase &gt; 1.67 times the upper limit of normal after 6 months of treatment
           with UDCA
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Response</measure>
    <time_frame>Week 24</time_frame>
    <description>Number of Participants with a decrease of alkaline phosphatase by &gt; 40%of the Day 0 level at 24 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Safety</measure>
    <time_frame>Weeks 2, 4, 12, 24, and 36</time_frame>
    <description>Number of participants with any adverse events, clinically significant changes in vital signs, laboratory test abnormalities, and clinical tolerability of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Alkaline Phosphatase</measure>
    <time_frame>Week 24</time_frame>
    <description>The absolute change in alkaline phosphatase from Day 0 to Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Alanine Transferase (ALT)</measure>
    <time_frame>Week 24</time_frame>
    <description>The absolute change in alanine transferase (ALT) from Day 0 to Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Stiffness Measured by Magnetic Resonance Elastography</measure>
    <time_frame>Week 24</time_frame>
    <description>Change in liver stiffness measured by magnetic resonance elastography from Day 0 to Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Billiary Cholangitis Quality of Life</measure>
    <time_frame>Week 24</time_frame>
    <description>Change in quality of life measured by change in primary biliary cholangitis (PBC)-40 from Day 0 to Week 24. is a patient-derived, disease specific quality of life measure developed and validated for use in PBC with subscores for domains of symptoms, itch, fatigue, cognition, social, and emotional. Subdomains are summed with a total score range of 36 to 200. Higher scores indicate worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Alkaline Phosphatase</measure>
    <time_frame>Week 24</time_frame>
    <description>The percent change in alkaline phosphatase from Day 0 to Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Alanine Transferase (ALT)</measure>
    <time_frame>Week 24</time_frame>
    <description>The percent change in alanine transferase (ALT) from Day 0 to Week 24.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunoglobulin M (IgM) Levels</measure>
    <time_frame>Week 24</time_frame>
    <description>Change in IgM level from Day 0 to Week 24</description>
  </other_outcome>
  <other_outcome>
    <measure>Memory T Cell Frequencies</measure>
    <time_frame>Week 24</time_frame>
    <description>Change in cluster of differentiation 4 (CD4)+ cluster of differentiation 44 (CD44)+ cluster of differentiation 62 ligand (CD62L)- and cluster of differentiation 8+ CD44+ CD62L- frequencies in peripheral blood mononuclear cells from Day 0 to Week 24</description>
  </other_outcome>
  <other_outcome>
    <measure>Abatacept Levels</measure>
    <time_frame>Day 0 and Weeks 4, 12, 24, and 36</time_frame>
    <description>Trough serum levels of abatacept</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Abatacept 125 mg weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label treatment with Abatacept</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>abatacept</intervention_name>
    <description>125 mg subcutaneously each week for 24 weeks</description>
    <arm_group_label>Abatacept 125 mg weekly</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed PBC diagnosis based upon at least 2 of 3 criteria

               1. Anti-mitochondrial antibody (AMA) titer &gt; 1:40

               2. Alkaline phosphatase &gt; 1.5 times the upper limit of normal for at least 6 months

               3. Liver biopsy findings consistent with PBC

          -  Incomplete response to UDCA defined by an alkaline phosphatase &gt; 1.67 X the upper
             limit of normal after 6 months of UDCA at a minimum dose of 13 mg/kg/d

          -  Taking a stable dose of UDCA for at least 3 months prior to Day 0

          -  aspartate aminotransferase (AST) and alanine aminotransferase ALT &lt; 5 times the upper
             limit of normal

        Exclusion Criteria:

          -  Presence of concomitant liver diseases including viral hepatitis, primary sclerosing
             cholangitis, alcoholic liver disease, Wilson's disease, hemochromatosis, or Gilbert's
             syndrome.

          -  Prior liver transplantation

          -  Decompensated liver disease

          -  Use of immunosuppressants within 6 months of Day 0

          -  Use of biologic agents within 12 months of Day 0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher L Bowlus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Eric Gershwin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pbcers.org</url>
    <description>PBC Patient Organization</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>March 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <results_first_submitted>January 27, 2020</results_first_submitted>
  <results_first_submitted_qc>March 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2020</results_first_posted>
  <last_update_submitted>March 28, 2020</last_update_submitted>
  <last_update_submitted_qc>March 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Christopher Bowlus, MD</investigator_full_name>
    <investigator_title>Professor, Gastroenterology and Hepatology, Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Primary Biliary Cirrhosis</keyword>
  <keyword>Ursodeoxycholic acid</keyword>
  <keyword>Abatacept</keyword>
  <keyword>Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 22, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02078882/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 22, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02078882/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Abatacept 125 mg Weekly</title>
          <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Abatacept 125 mg Weekly</title>
          <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="39" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemical Response</title>
        <description>Number of Participants with a decrease of alkaline phosphatase by &gt; 40%of the Day 0 level at 24 weeks of treatment.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abatacept 125 mg Weekly</title>
            <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Response</title>
          <description>Number of Participants with a decrease of alkaline phosphatase by &gt; 40%of the Day 0 level at 24 weeks of treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Safety</title>
        <description>Number of participants with any adverse events, clinically significant changes in vital signs, laboratory test abnormalities, and clinical tolerability of the drug.</description>
        <time_frame>Weeks 2, 4, 12, 24, and 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abatacept 125 mg Weekly</title>
            <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Safety</title>
          <description>Number of participants with any adverse events, clinically significant changes in vital signs, laboratory test abnormalities, and clinical tolerability of the drug.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Alkaline Phosphatase</title>
        <description>The absolute change in alkaline phosphatase from Day 0 to Week 24.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abatacept 125 mg Weekly</title>
            <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Alkaline Phosphatase</title>
          <description>The absolute change in alkaline phosphatase from Day 0 to Week 24.</description>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" lower_limit="-97.5" upper_limit="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Alanine Transferase (ALT)</title>
        <description>The absolute change in alanine transferase (ALT) from Day 0 to Week 24.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abatacept 125 mg Weekly</title>
            <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Alanine Transferase (ALT)</title>
          <description>The absolute change in alanine transferase (ALT) from Day 0 to Week 24.</description>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-13.5" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Stiffness Measured by Magnetic Resonance Elastography</title>
        <description>Change in liver stiffness measured by magnetic resonance elastography from Day 0 to Week 24.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abatacept 125 mg Weekly</title>
            <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Stiffness Measured by Magnetic Resonance Elastography</title>
          <description>Change in liver stiffness measured by magnetic resonance elastography from Day 0 to Week 24.</description>
          <units>kPa</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.43" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Billiary Cholangitis Quality of Life</title>
        <description>Change in quality of life measured by change in primary biliary cholangitis (PBC)-40 from Day 0 to Week 24. is a patient-derived, disease specific quality of life measure developed and validated for use in PBC with subscores for domains of symptoms, itch, fatigue, cognition, social, and emotional. Subdomains are summed with a total score range of 36 to 200. Higher scores indicate worse quality of life.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abatacept 125 mg Weekly</title>
            <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Billiary Cholangitis Quality of Life</title>
          <description>Change in quality of life measured by change in primary biliary cholangitis (PBC)-40 from Day 0 to Week 24. is a patient-derived, disease specific quality of life measure developed and validated for use in PBC with subscores for domains of symptoms, itch, fatigue, cognition, social, and emotional. Subdomains are summed with a total score range of 36 to 200. Higher scores indicate worse quality of life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-4" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Alkaline Phosphatase</title>
        <description>The percent change in alkaline phosphatase from Day 0 to Week 24.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abatacept 125 mg Weekly</title>
            <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Alkaline Phosphatase</title>
          <description>The percent change in alkaline phosphatase from Day 0 to Week 24.</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.28" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Alanine Transferase (ALT)</title>
        <description>The percent change in alanine transferase (ALT) from Day 0 to Week 24.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abatacept 125 mg Weekly</title>
            <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Alanine Transferase (ALT)</title>
          <description>The percent change in alanine transferase (ALT) from Day 0 to Week 24.</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.29" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immunoglobulin M (IgM) Levels</title>
        <description>Change in IgM level from Day 0 to Week 24</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Abatacept 125 mg Weekly</title>
            <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Immunoglobulin M (IgM) Levels</title>
          <description>Change in IgM level from Day 0 to Week 24</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-44.0" upper_limit="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Memory T Cell Frequencies</title>
        <description>Change in cluster of differentiation 4 (CD4)+ cluster of differentiation 44 (CD44)+ cluster of differentiation 62 ligand (CD62L)- and cluster of differentiation 8+ CD44+ CD62L- frequencies in peripheral blood mononuclear cells from Day 0 to Week 24</description>
        <time_frame>Week 24</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Abatacept Levels</title>
        <description>Trough serum levels of abatacept</description>
        <time_frame>Day 0 and Weeks 4, 12, 24, and 36</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 weeks</time_frame>
      <desc>Adverse events were summarized according to MedDRA System Organ class, MedDRA preferred term, severity and causal relationship assessed by investigators and were reviewed by Data Monitoring Board.</desc>
      <group_list>
        <group group_id="E1">
          <title>Abatacept 125 mg Weekly</title>
          <description>Open label treatment with Abatacept
abatacept: 125 mg subcutaneously each week for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hilar Adenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Nausea">Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Right upper quadrant pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticarial Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher L Bowlus</name_or_title>
      <organization>University of California Davis</organization>
      <phone>9167348696</phone>
      <email>clbowlus@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

